Guggenheim Capital LLC Cti Biopharma Corp Transaction History

Guggenheim Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$3.81 - $5.26 $62,289 - $85,995	-16,349 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$2.7 - $4.06 $12,147 - $18,265	4,499 Added 37.97%	16,349 $64,000
Q4 2017 Feb 14, 2018	SELL	$2.47 - $3.34 $3,655 - $4,943	-1,480 Reduced 11.1%	11,850 $32,000
Q3 2017 Nov 14, 2017	BUY	$3.12 - $3.65 $41,589 - $48,654	13,330	13,330 $43,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.